GlassScriptPhysician profile
Lydia Hodge
NPI 1578136701
$1,909.09
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $154 · 2022: $860 · 2023: $878 · 2024: $17.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $894.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $334.43 | 2021-2023 | Mounjaro, Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $235.32 | 2022 | |
| Abbvie INC. | $211.21 | 2022-2024 | |
| Pfizer INC. | $179.53 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $133.44 | 2022-2023 | |
| Amgen INC. | $118.59 | 2022-2023 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $100.23 | 2022-2023 | Arexvy, Shingrix |
| Novo Nordisk INC | $74.87 | 2023 | Rybelsus, Ozempic, Wegovy |
| Scilex Pharmaceuticals INC. | $74.83 | 2023 | Ztlido |
| Lundbeck LLC | $73.04 | 2022-2023 | Vyepti |
| Esperion Therapeutics, INC. | $56.94 | 2022-2023 | Nexletol |
| Biohaven Pharmaceuticals, INC. | $49.02 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.98 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $36.95 | 2022-2023 | Quviviq |
| Biogen, INC. | $30.43 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $27.31 | 2022-2023 | Verquvo, Steglatro, Belsomra |
| Otsuka America Pharmaceutical, INC. | $19.35 | 2023 | Rexulti |
| Bausch Health US, LLC | $17.91 | 2023 | Aplenzin |
| Exact Sciences Corporation | $17.79 | 2023 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $17.18 | 2022 | |
| Eisai INC. | $17.12 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.19 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $12.72 | 2023 | Breztri |
| Sanofi-Aventis U.S. LLC | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lydia Hodge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.